Skip to content Skip to site navigation Skip to local navigation
Department of Health

Medical Services Advisory Committee

  • MSAC
  • About MSAC
    • About MSAC
    • MSAC Process Framework
    • MSAC Executive Terms of Reference
    • MSAC Terms of Reference
    • MSAC Membership
    • ESC Terms of Reference
    • ESC Membership
    • PASC Terms of Reference
    • PASC Membership
    • Frequently Asked Questions
  • MSAC Meetings
    • Meetings
  • Public Funding
    • How to Apply for Public Funding
  • Forms Templates & Guidelines
    • Assessment Groups
    • Applicants
  • Guidelines Review
    • Guidelines Review
    • Guidelines Review Webinars
  • MSAC Applications
    • Application Page
  • Utilisation Monitoring Process
  • You are here:
  • Medical Services Advisory Committee /
  • MSAC Meetings /
  • Meetings /

ESC Meeting - 12 June 2020

Page last updated: 30 June 2020

Evaluation Sub-Committee - Applications considered


  • 1569 - Chitosan-based cartilage biomatrix implant (BST-CarGel), in conjunction with the marrow stimulation technique (microfracture), for repair of focal cartilage defects
  • 1573 - Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis
  • 1575 - Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, breast cancer treatment/prevention and congenital breast deformity
  • 1577 - Autologous fat grafting (AFG) for treatment of burn scars, and treatment of facial defects due to craniofacial abnormalities
  • 1582 - Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of NMO (neuromyelitis optica)
  • 1586 - Transurethral Water Vapour Ablation (TUWA) for benign prostate hyperplasia (BPH)
  • 1590 - Review of immunoglobulin use - Multifocal Motor Neuropathy (MMN)
  • 1593 - Bovine bioinductive collagen implant (REGENETENTM)
  • 1612 - Prostatic urethral lift procedure for men with benign prostate hyperplasia
  • 1622 - Cardiac ablation devices for use in ventricular arrhythmia and supraventricular tachycardia
  • 1623 - LuxturnaTM (voretigene neparvovec) for the treatment of biallelic RPE-65-mediated inherited retinal dystrophies
  • 1625 - Dinutuximab beta for treatment of high risk neuroblastoma
Listen
  • MSAC Meetings
  • Meetings
    • MSAC – ESC Calendar Key Dates
    • PASC Calendar Key Dates
    • Co-dependent Technologies
  • MSAC Email Bulletin


  • Feedback
Provide feedback

Comments will be used to improve web content and will not be responded to.

Real person check

This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


Privacy statement

Your feedback has been submitted

Thank you for taking the time to provide feedback. It will be used to make improvements to this website.

Medical Services Advisory Committee

Medical Services Advisory Committee

© Commonwealth of Australia
ABN: 83 605 426 759

MBS Information

  • MBS Online
  • Legislation that covers the MBS
  • About MBS Factsheets
  • MBS Review

HTA Information

  • What is HTA
  • Australian Government HTA processes

Useful Links

  • MBS Online
  • PBS
  • PBAC
  • PLAC
  • Health Technology Reference Group
  • Healthier Medicare
  • MBS Review
  • TGA
  • HTA Conflict of Interest Guide

About

  • Copyright
  • Linking to this site
  • Accessibility
  • Disclaimer
  • Privacy
  • What is RSS?
  • Contact Us